Book icon

The most prescribed treatment for multiple myeloma in 1st line and beyond3*

Category icon

Category 1 National Comprehensive Cancer Network® (NCCN®) recommended for first line and beyond4‡

World icon

More than 1 million patients treated globally since 20031,3†

Needle icon

1 convenient subcutaneous option§ for patients vs IV4-6

NCCN makes no warranties of any kind whatsoever regarding their content, use, or application and disclaims any responsibility for their application or use in any way.

*Based on data collected from October 2018 through September 2020.

As of April 2020.3

Specifically designated for VRd only.

§Also available for intravenous (IV) use.

VRd=VELCADE, REVLIMID (lenalidomide), dexamethasone.